Saturday, May 11 2024
10:30 AM – 10:45 AM ET - Room 307-308
395: RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data
Jahannaz Dastgir
REGENXBIO Inc.
Disclosures: J. Dastgir: 1; Commercial Interest i.e. Company X; REGENXBIO Inc.. 1; What was received? i.e. Honorarium; Salary, Stock Options. 1; For what role? i.e. Speaker; Employee.
Related Abstract